Loading cancer entity…
Loading cancer entity…
Clinical trials
10 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07072676 | The Use of Assistive Gait Devices Can Reduce the Risk of Falls in Patients With Neuromuscular Diseases Following a Training Period.(Risk of fall) | enrolling by invitation | N/A | 30 | LMU KlinikumOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT05513365 | Phase II Dutasteride in Combination With CAB vs CAB in SDC(DUCT) | recruiting | Phase 2 | 26 | Radboud University Medical CenterOTHER | 1 | Jun 4, 2025 |
| clinicaltrials |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | terminated | Phase 1 | 40 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04291300 | Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients(LUPSA) | completed | Phase 2 | 12 | Radboud University Medical CenterOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT04214353 | PSMA-PET Imaging Before and After ADT in Advanced SDC Patients(ADT-SCAN) | unknown | N/A | 14 | Radboud University Medical CenterOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03614364 | Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma | unknown | Phase 2 | 41 | Samsung Medical CenterOTHER | 1 | Jan 4, 2022 | clinicaltrials |
| NCT03319641 | PSMA-PET Imaging for Advanced ACC/SDC | completed | N/A | 25 | Radboud University Medical CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT00095563 | Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Apr 18, 2017 | clinicaltrials |
| NCT00126607 | Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00028496 | Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Jul 18, 2025source: clinicaltrials